Farmington-based immunotherapy startup CaroGen reports it has won a $1.4 million grant from the National Institutes of Health to accelerate development of its lead drug candidate, a potential cure for chronically infected hepatitis B (HBV) patients.
CaroGen’s CEO, President, and Co-founder, Bijan Almassian, PhD, stated, “Receiving a total of $1,625,000 so far in SBIR funding in support of our HBV program is a testament to the quality and competitiveness of our data, our sound development plan, and the promise of CARG-201 as a novel immunotherapy for the potential cure of HBV.”